Thursday, October 22, 2020
Home Regulatory Affairs Drug Approval Process in China

Drug Approval Process in China

The National Medical Products Administration (NMPA) ( Chinese name translation in English “State Drug Administration” or China Food and Drug Administration CFDA)  and the Ethical Committee must approve a clinical trial application prior to the sponsor initiating a clinical trial.

First EC approves the application and NMPA’s approval depends on it.  China Follows the centralized process for ethical review of the clinical trial application.

- Advertisement -

The ethical review process has three layers:  national EC, provincial ECs, and institutional level ECs.

China’s National Health Commission (NHC) is responsible for managing ECs nationwide by establishing the National Committee of Medical Ethics Experts which develop policies for ethical review.

Please see the below tables for a comprehensive view of the drug approval process.
The drugs are characterized into 5 Categorize as per New regulation by CFDA on Mar-2016.
Credit: https://www.sfdachina.com/info/202-1.htm

Classification of Drugs and Definition


Clinical Trial Requirements

https://www.sfdachina.com/info/202-1.htm

The drug approval process in other countries:

Drug Approval process-FDA
Drug Approval process-FDA
Big Change in FDA process for Biologics:
The Drug approval process in EU:
Drug Approval Process in India
Orphan Drug Designation in US, EU and Japan
Approval pathways of Fixed dose combination (FDC) in India

LEAVE A REPLY

Please enter your comment!
Please enter your name here

14 − eight =

Most Popular

AZ’s Tagrisso scores priority review from FDA with EGFR-mutated lung cancer

October 20, 2020: "AstraZeneca’s Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in...

Forxiga recommended for approval in the EU by CHMP for heart failure

October 19, 2020: "AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the...

AstraZeneca advances leadership in renal disease at ASN Kidney Week 2020 Reimagined

October 20, 2020: AstraZeneca will present 84 abstracts, including 12 oral presentations and three late-breaking abstracts, across its industry-leading renal portfolio which...

AbbVie’s VENCLEXTA® Receives FDA Approval for Acute Myeloid Leukemia

October 16, 2020: "AbbVie announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination...